These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21664897)

  • 1. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.
    Lainey E; Thépot S; Bouteloup C; Sébert M; Adès L; Tailler M; Gardin C; de Botton S; Baruchel A; Fenaux P; Kroemer G; Boehrer S
    Biochem Pharmacol; 2011 Nov; 82(10):1457-66. PubMed ID: 21664897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
    Boehrer S; Adès L; Galluzzi L; Tajeddine N; Tailler M; Gardin C; de Botton S; Fenaux P; Kroemer G
    Biochem Pharmacol; 2008 Dec; 76(11):1417-25. PubMed ID: 18617157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
    Boehrer S; Adès L; Braun T; Galluzzi L; Grosjean J; Fabre C; Le Roux G; Gardin C; Martin A; de Botton S; Fenaux P; Kroemer G
    Blood; 2008 Feb; 111(4):2170-80. PubMed ID: 17925489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
    Lainey E; Wolfromm A; Marie N; Enot D; Scoazec M; Bouteloup C; Leroy C; Micol JB; De Botton S; Galluzzi L; Fenaux P; Kroemer G
    Oncogene; 2013 Sep; 32(37):4331-42. PubMed ID: 23085751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
    Tong FK; Chow S; Hedley D
    Cytometry B Clin Cytom; 2006 May; 70(3):107-14. PubMed ID: 16498671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
    Groves MJ; Sales M; Baker L; Griffiths M; Pratt N; Tauro S
    Cancer Genet; 2011 Jan; 204(1):39-44. PubMed ID: 21356190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
    Eriksson A; Höglund M; Lindhagen E; Aleskog A; Hassan SB; Ekholm C; Fhölenhag K; Jensen AJ; Löthgren A; Scobie M; Larsson R; Parrow V
    Biochem Pharmacol; 2010 Nov; 80(10):1507-16. PubMed ID: 20705060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
    Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
    Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
    Morgan MA; Reuter CW
    Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
    Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
    Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofibric acid: a potential therapeutic agent in AML and MDS.
    Fenton SL; Drayson MT; Hewison M; Vickers E; Brown G; Bunce CM
    Br J Haematol; 1999 May; 105(2):448-51. PubMed ID: 10233420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of signaling in myelodysplastic syndrome.
    Gore SD
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):613-22. PubMed ID: 15494298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
    Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.